Azathioprine, a thiopurine compound that exhibits immunosuppressive activity is currently used with cyclosporine and corticosteroid in combined immunosuppmssive protocols in organ transplantation (1). Azathioprine undergoes a complex metabolic pathway and its pharmacodynamic activity is considered to depend on the formation of intracellutar thiopurine nucleotides (2). Despite the extensive use of azathioprine in lung transplantation, data on diffusion of thiopurine nucleotides into the lung are not available. Therefore, we investigated lung distribution of thiopurine nucleotides of 6-thioguanine (6TGN), 6-mercaptopudne (6MPN) and 6-thioxanthine (6TXN) in eigth lung-transplant patients under azathioprine therapy.
Both arms of the adenine nucleo%ide cycle (IMP to AMP and AMP to IMP) are operating in the cultured neurons, but, the intensity of this cycle has not yet been clarified and it is not known yet if this cycle has any slgnificant role in this tissue, other than synthesis and degradation of AMP.
DETECTION OF POINT MUTATIONS AT THE HUMAN HPRT-LOCUS USING THE RAPID SINGLE STRAND CONFORMATION POLYMORPHISM (S$CP) ANALYSLS
Renate Buroemeister. Elke Rotzer, Wolf Gutensohn
Complete deficiency of HPRT causes the Lesch-Nyhan syndrome (LNS) which is characterized by hyperuricemia, mental retardation, choreoathetosis, and compulsive self4"nutilation. Partial deficiency of HPRT leads to a severe form of gout and nephtolithiosis.
Here we describe three mutations in three nonrelated families previously studied by direct sequencing of PCR products of the human HPRT gene.
* Patient IJ shows an insertion of one G in exon 3 of the HPRT gene. He represents a case of the classical Lesch-Nyhon syndrome. There is no residual activity of HPRT in his erythrooyte lysate. His mother is heterozygous for the disease whilst his sister shows no mutations, * Patient GS has a mutation in exon 7 (CGA -> TGA, Are --> Stop). He shows a partial HPRT-deficlency, a residual activity of 1,8% of normal is found in his erythrooyte Iysate. His mother shows no rt,,utation, so it is assumed that this is a case of a new mutation. * Patient KM has a point mutation in exon 2 (ATr --:, ITT, lle --> Phe) and he shows a partial HPRT-deticiency. His residual activity of HPRT is 2.7% of normal, His mother is heterozygous.
Patients GS and KM represent clinical borderline cases, including not only the symptoms of gout, but also some of the neurological symptoms of LNS lacking the the typical autoaggressive behavior.
For the rapid arid simple detection of point mutations we used the single strand conformation polyrnorphlsm (SSCP) analysis. Single stranded DNA molecules ore capable of forming unique secondary structures whose nature is dependent upon their base sequences, The type and degree of secondary structure formation in turn determines electrophoretic mobility under nondenaturing conditions. Mutations within a given DNA segment alter this mobility and the "mobility shift" may be detected on high resolution native PolyacryJamid gels.
We demonstrate that SSCP analyf~s can reliably and reproducibly identitiy the mutations we had found previously in three exons of the human HPRT gene. All mutations detected by direct DNA sequencing were also detecled by SSCP in all probands tested. Individuals homozygous and heterozygous for the mutations in this X chromosomal disease are olearly distinguishable.
The simpl~ity of this technique together with its speed and reliability commend it for routine use in molecular diagnostic medicine. In the cardiovascular system there is some evidence in favour of the presence of extracellular receptors that are activated specifically by uridine 5'-triphosphate (UTP) rather than adenosine 5'-triphosphate (ATP) i.e., pyrimidinoceptors, however it is unknown if these receptors also exist within the nervous system. We bare investigated this possibility using methods described before 1.
SCG were placed in a chamber and perfused with physiological salt solution+(PSS) at 25+ I~ 7.4 equilibrated with 5% CO,V95%O 2 containing 2raM K and 0. I mM Ca 24. The d.c. potential between the ganglion and the postganghomc nerve was recorded across a greased barrier, Adenosine and pyrimidines were added to the perfu~ate for 2 rain and other drugs for 1 rain. Responses in the presence of atropine (2aM) or suramin (300,aM) were determined after I5 or 30 rain preincubation.
On the same ganglia UTP was more potent thatl a/bMeATP in producing concentration -dependent depolarisatioos. Depolarisations caused by aBMeATP were abolished by suramin, whereas depolarisation caused by UTP were potentiated, and hyperpolarisations to adenosine, depolarisatioas to muscarine, DMPP or K + remained unaltered (Table 11 . In the presence of suramirr, atropine abolished depolarisations caused by muscarine (100nM, 276 _+ 33~V cf 6 _ 7~tV, n=4, P<0.01) but not those caused by 100~M UTP (263 -+ 67,aV cf200 4-41/xV, n=4).
Effect of suramin on thexesoonse (uV, me,.a~t +/-s.e.mean (4-9 SCGI. .= P < 0_01.*~* P < 0.01. Paired t-test/to denoladsing and h yoemolarisin~_aeooists. A~anist ~/bMeATP UTP Adenosine Muscarine DMPP K +  Tceatment  100ttM  100~M  I00#M  100nM  10uM  3mM  CONTROL  76+I1  216_+38 -1405:35 231_+32 1214-27 136+_33 SURAMIN -5_10"** 2834-44"*-161• 268+29 139_+35 1144-28
The inability of atropine to alter depoiarisation to UTP indicates that UTP did not depolarise ganglia by releasing acetylcholine to activate muscarinic receptors or activate muscarinic receptors directly. The selective antagonism of the response to uBMeATP and not UTP by suramin is consistent with the presence of both P2-purinoceptors and receptors for UTP. Our results provide evidence for the presence of pyrimidinoceptors in the nervous system and suggest that the rat SCG may be a useful model system for studying these receptors. 
FENOFIBRATE:
A LIPID LOWERING DRUG WITH URICOSURIC PROPERTIES U. Gresscr, Fenofibrate, a fibric acid derivate, is used for the treatment of hyperlipoproteinemias. In addition to its lipid lowering properties feaofibratr shows a uricosoric effect. In healthy volunteers feoofibrate lead to a 2-fold, benzbromarone t9 a 4-fold increase of uric acid clearance I. In hyperuricemic outpatients the decrease in plasma uric acid over a period of one year was 30 % of the initial value 2. Other authors found a decrease of plasma uric acid of 20 %3, 4 In comparison hczafibrate and placebo had no uricosuric effect 3. Most of these studies were performed to measure the lipid lowering effect of fenofibrate and therefore give no detailled informations on extent and course of time of the uricosuric effect of fenofibrate. Aim of our study was to get detailled informations on these points in comparison to a well-known uricosaric drug. We compared the uricosurie and lipid lowering effects of a single daily dose of fenofibratc (200 mg, micronized, Knoll AG) with benzbromaxone (100 rag, ratiopharm) in a cross-over study with 7 healthy volunteers on a low purine dict. Our results confirm the observations of a distinct uricosoric effect of fenofibrate. In 7 healthy volunteers a single dose of 200 mg fenofibrate lead to an average additional renal uric acid excretion of 204 mg Coenzbromarone: 376 rag) within 14 hours after drug ingestion. So fenofibrate lead to 54 % of the additional renal uric acid excretion in comparison to benzbromarone in the same volunteers. If we include that the normal dally dose of beazbromarone would be 80 rag, the relative uricosurie effect of feoofihrate is more impressive. Between hyperurieemia and hypertriglyceridemia there is a significant correlation (p<0,001) 5. Therefore many patients need a uric acid lowering and a lipid lowering treatment. Fenofibrat preferentially is a lipid lowering drug, but with its clear uricosuric properties it could be a good possibility in many patients with both metabolic diseases. The uricosaric effect of fenofibrate is large enough to normalize uric acid in most patients with hyperlipidemia and hyperuricemia. With its combined lipid lowering and uricosuric properties fenofibrate will help to shed light on the pathophysiology of the correlation between hyperlipidemias and hyperuricemia. We give detailled informations on the influence of fenofibrate and benzbromarone on plasma uric acid, renal uric acid excretion, triglycerides, HDL-and LDL-cholesterol. 
MAGNETIC RESONANCE IMAGING ENLARGES THE DIAGNOSTIC POSSIBILITIES IN HYPERURICEMIA AND GOUT
I. Kamilli I, U. Gresser 1, R. Rauch 1 , D. Hahn 2
In patients with chronic gout uric acid deposition appears in bones near to joints, in the synovial membrane, in bursae, tendon sheats and other bradytrophical tissues. Whereas bone tophi and superficial tophi are well accessible, tophi in non superficial tissues, e.g. heart valves, eyes, spine and peripheral nerves, can not be identified and we find them only surgically or by autopsy. The purpose of this study was to investigate the valuation of scintigraphy and magnetic resonance imaging (MR/) in comparison to clinics and conventional radiological procedures for demonstration of uric acid deposition.
Twentyfive patients with chronic gout followed in the Medizinische Poliklinik participated in this study. In every patient (n=25) radiographs of the feet, big toe, ankle joints, knees, hands, wrists and elbows (joint region=350) and an early (5 min) and late (2 hours) static scintigraphy (99mTcPP) were obtained. In 9 patients, 7 feet, 6 hands and one elbow a MRI was done. Coronal, axial and sagittal T1 and T2 weighted MR images with and without Gd-DTPA were obtained. We compared the findings in MRI, clinical evaluation, x-ray and scintigraphy in every joint region. In MRI in 14 (100%) joint regions soft-tissue tophi were found, whereas in clinical evaluation and x-ray only in 8 joint regions tophi were registrated and in scintigraphy only in 11 joint regions higher concentrations of activity were found. In MRI tophi appear in TI weighted images as hypotense inhomogenous structures and in T2 weighted images as hyperintense structures. With Gd-DTPA tophi appear in T1 weighted images as structures enhancing the contrast medium; in larger tophi there is only a peripheral enhancement and a central zone with a tow signal intensity. In contrast to all the other diagnostic possibilities only in MR/bone marrow edema are obtained as a sign of inflammation.
MRI is the only method to mark off the complete extension of tophi. Therefore MR/enlarges the diagnostic possibilities in hyperuricemia and gout, especially the diagnosis of the extend of tophi in non superficial tissues, e.g. eyes, spine, skullbase and perineural tissues such as the carpal tunnel.
I Medizinische Poliklinik der LMU-Mftnchen, Pettenkoferstr. $a, 80366 Mfinchen, Germany 2Radiologische Polikliaik der LMU-Mfinchen, Pettenkoferstr. 8a, 80366 Mtnchem Germany
AICARIBOSIDE INHIBITS GLYCOLYSIS IN HEPATOMA CELLS

F. Javaux. MF. Vincent. G. Van den Bemho
AICAriboside, the nucleoside corresponding to AICAR (ZMP), an intermediate of de nove purine synthesis, inhibits glycolysis in isolated rat hepatocytes (t).
Since many tumour cells depend on a high glycotytic rate (2) to provide the energy required for proliferation, the effect of AICAriboside was investigated in the rat hepatoma cell line FTO-2B.
In intact FTO-2B. cells, addition of 250 l.tM AICAriboside resulted in the accumulation of 5 mM ZMP. Production of lactate with 10 mM glucose was inhibited by 65% within 2 h. Half-maximal inhibition was reached with 50-100 p.M AICAdboside. Iodotubercidin, an adenosine kinase inhibitor, suppressed the effect, implying that phosphorylation of AICAriboside by this enzyme was required. Further investigations revealed that AICAriboside displayed two major effects: (i) It decreased the release of 3H20 from [2-3H]glucose, synchronously with the inhibition of the production of lactate. This ,indicates inhibition of glucose transport or of an early step of glucose metabolism: phosphorylation into glucose-6-P (by hexokinase in FTO-2B cells), or isomerisation of glucose-6-P into fructose-6-P.
(ii) It decreased the concentration of fructose-2,6-P 2, the main stimulator of phosphofructokinase (PFK)-I. This effect, which required at least 4 h of incubation, did not result from inactivation of PFK-2, but most probably from a decrease of fructose-6-P, due to inhibition of an early step of glucose metabolism. Fructose-l,6-P 2 decreased, most likely owing to the diminished stimulation of PFK-I.
In cell-free extracts of FTO-2B cells, phosphoglucose isomerase was 70% inhibited by 5 mM ZMP. Implication of this effect in the inhibition of glycolysis was, however, ruled out because residual activity remained 100-fold higher than that of hexokinase. Although no direct inhibition of hexokinase activity by ZMP could be evidenced as yet, it is tentatively concluded that A$CAriboside, by a still to be defined mechanism, primarily inhibits this enzyme. At longer time intervals, the inhibitory effect of AICAriboside on glycolysis is reinforced by the subsequent decrease of fructose-2,6-P2. The mode of action of 6-mercaptopurine (6MP) in vitro is based on incorporation into DNA and RNA as thioguanine nuclcotides and inhibition of the purine de hove synthesis by methylthioinosinic monophosphate (MetlMP). We studied the metabolic routes of 6MP in 6 lymphoma patients receiving 24 hours infusions of 6MP. Pharmacokinetics, intracellular biochemistry and pharmacology were studied in plasma, erythrocytes and mononaclear cells. Blood samples were collected at 0, 4, 20, 24, 28 and 48 hours after start of the 6MP infusion (100 rag/m: in 0.5 hr followed by 1200 mg/m 2 in 23.5 hr). 6MP, its metabolites, ribonucleotides, nuclcosidas and bases were measured by HPLC. .: In plasma steady state levels of 6MP were reached soon after administration of 6MP in a concentration range of (~50 FM. Methylmercaptopurine (MeMP) appeared at t=4 (0.3-3 p.M) and the concentration decreased rapidly, like 6MP, after the end of the infusion. Methylmercaptopurineriboside (MeMPR) appeared at t=20 and remained at a steady state level (0-0.4 /~M) from t=24 till t=48. Two patients had a tumor lysis syndrome before start of the 6MP treatment. They demonstrated extremely high 6MP levels (35-60 ~.M) and longer 6MP half-life times. Relatively high MeMP levels (2-3 #M) and no MeMPR could be detected in these patients. Only these two patients had measurable amounts of thioxanthine at extremely high levels (10-40/~M). MetlMP in erythrocytes was detected at t=4 and reached, like MeMPR, a steady state level (15-2000 pmol/10 m cells) at t=24. MetlMP in mononuclear cells (2-20 pmol/l(P ceils) was detected from t=20. The patients with a tumor lysis syndrome reached lower MatlMP levels as compared to the other children. Intraeellular thioguanine nuclcotides could not be detected in any of the patients, probably because these metabolites are rapidly incorparated into DNA. These data show large differences in 6MP metabolism in lymphoma patients. Patients without tumor lysis are probably able to incorporate 6MP into DNA and RNA and their blood cells contain MetlMP for more than 24 hours. In plasma of these patients no thioxanthine and less MeMP was detected. So, the anabolic route of 6MP in the cells of these patients is high. In contrast, in patients with a tumor lysis syndrome the catabolic route of 6MP is predominant: high levels of thioxanthine and relatively large amounts of MeMP. Our hypothesis for the predominant catabolic route of 6MP in tumor lysis patients is based on an excess of free nuclcosides and bases, derived from the lysis of tumor cells. The purine nuclcosides and bases may then compete with 6MP for the enzyme hypoxanthineguanine phosphoribosyltransferase. This hypothesis is supported by the finding of high plasma levels of hypoxanthine (6 and 85 #M) and xanthine (25 and 350/~M) in these two patients.
Center for Pediatric Oncology, University Hospital, P.O.B. 9101, 6500 HB Nijmegen, The Netherlands. This project is supported by the DutchCancer Society (NUKC-92-79). In the present study the enzyme dihydroorotate:ubiquinone o~dore-ductase (DHO DH] was investigated in tissue samples of rat and man, and in a mouse mamma carcinoma cell llne. Since the rnitochondrial DHO DH is connected to the functional respiratory chain 1, the enzyme activity could beevaluated tn s/tu by channelling the redox equivalents to artificial electron acceptors after cyanideblocking of the chain at the stage of cytochrome oxidase. The principle of the techniques used for the detection of the dehydrogenase activity was to employ a colourless, soluble tctrazolium salt which is reduced to a deeply coloured, insoluble formazan product. This could be detected by light microscopy, and, in a first approach, by flow cytometry if a fluorescent formazan was produced. The specificity of the dihydroorotate-dependent formazan production was confn'med using enzyme-inhibiting drugs of high potency. The activity-pattern of DHO DH was comparable to that of succinate dehydrogenase, a marker of inner mitochondrial membrane. High activities were found in tissues with known transport/excretlon/regeneration/proliferatlve activities. The additional oxidase activity of the DHO DH, which was measured with the purified enzyme 2, was demonstrated/n s/tu by employing the cerium/diaminobenzldine method for trapping the hydrogen peroxlde resulting from direct reaction with oxygen. An unusual high o~ddase activity could be detected in the cardiac muscle by light microscopy. This was verified by ultrastructural studies which localized a cerium precipitate of high electron density at the inner mitochondrial membrane. In media with high Na-concentration like Ringer HEPES buffer and at low pH (e.g. 6.5) the intraceUular concentration of Pi (about 10 raM) increases by a factor of only about 2 with increasing extracelhilar Pi (up to 45 re_M). Neverthaless the presence of purina riboside (nebular/he) may cause not only a drastic decrease in intraceUular Pi but also a rapid uptake of extracellular Pi resulting in accumulation of large amounts of purina riboside trlphosphate. The linear increase in purine riboslde triphosphate may in about 2 h result in a total content of low ~nolecular phosphate compounds that is about 10-fold that of cells not treated with purine riboside. It thus appears that the intracellular phosphorylatiou of purine riboside facilitates a greatly increased net uptake of Pv In media-buffers with a high K-concentration increasing concentration of extraceUular Pi gives rise to an unexpected high rate of accumulation of intracellular Pi. Under such conditions, or at high pH values (e.g. 7,9), the total Pi uptake was almost unaffected by the presence of purine ribosids even though considerable amounts of it were converted to the triphosphate. FJHN has often been considered 'familial nephritis' until an isolated attack of gout (rare in renal failure) has highlighted the underlying disorder.
Gout and hypertension are inconsistent features.
The genetic basis remains unknown.
FJHH has, hitherto, been considered rare. Detailed studies of 88 cases from 14 kindreds have been reported from 7 countries, excluding the UK, 36 of these cases have been children. We have now studied 90 individuals from 34 kindreds in which the index case presented with gout and found that the hallmark of the disease is hyperuricaemia associated with a low clearance of uric acid relative to creatinine (FEur), disproportionate to age, sex and degree of renal failure.
On this criteria we identified 65 affected individuals, 25 of whom were reputedly healthy. The study included 27 children (one a female seen with gout at 9 years).
A reduced FEur has been found in 18 of the children, including 5 with as yet normal renal function, suggesting that renal urate hypoexcretion precedes a fall in the GFR.
Our findings indicate that FJHN is also a disease of childhood.
They underline the importance of detailed family studies in all kindred members. This is essential since, in our experience; a) allopurinol appears to have ameliorated the progression of the renal damage in patients treated for up to 25 years; b) a successful prognosis appears to depend on the renal function at diagnosis and the absence of hypertension, or its adequate control. 2',2'-difluoro-deoxycytidine (Gemcitabine, dFdC) is a deoxycytidine analogue with established anti-tumour activity in the clinic, dFdC is assumed to exert its antitumour effect through incorporation into DNA. Since the RNA-directed effects were not clearly defined, we studied the incorporation of dl:dC into DNA and RNA and its effect on nucteic acid synthesis. We determined incorporation of dFdC into nucleic acids of A2780, a human ovarian carcinoma cell line, Colon 26-10, a mudne colon carcinoma cell line and in CCRF-CEM, a human leukemic cell line. For this purpose we used two different methods; an acid precipitation assay and a CsCI density gradient, after exposing the cells for 4 or 24 h to 0.1 or 1 I~M dFdC. Synthesis of DNA was determined by [2-14C]-thymidine (14C-TdR) incorporation, RNA synthesis by [5-3H] -uridine (3H-UR) incorporation. Incorporation of dFdC into DNA was time and concentration dependent. A2780, the most sensitive to dFdC, incorporated most dFdC (3-'7 fold compared to C26-10). We also observed incorporation into RNA, which was only concentration dependent, within the time period used. The solid tumour cell lines incorporated much more dFdC into RNA (6-14 fold) than the leukemic cell line, especially at 1 I~M dFdC. dFdC incorporation into RNA was confirmed by separation of RNA and DNA using CsCI gradient centrifugation. The same pattern was observed as w~th the acid precipitaion assay, while contamination of RNA by DNA was less than 0.4%. As to the synthesis of the nucleic acids, in all three cell lines dFdC inhibited DNA synthesis completely, at 1 I~M after 24 h exposure. RNA synthesis could be inhibited completely only in CCRF-CEM ceils, after 24 h exposure to 1 p.M of dFdC. In the two solid tumeur cell lines RNA synthesis was also inhibited, however to a maximum of 60%.
In conclusion, dFdC interferes with both DNA and RNA synthesis. The latter effect has not been recognized before and it has to be determined wether it is related to either anti-tumour activity or toxicity. Brief period of ischemia causes increase in adenosine and total purine catabolite release from the heart. However, if ischemia of similar duration is repeated, this increase in purine catabolite release is markedly reduced. The mechanism of this phenomenon is unclear. In this study an isovolumic Langendorff perfused rat heart model was used. Hearts were subjected to (A) 1 min ischemia at 40 rain of perfusion, 10 rain ischemia at 50 rain of perfusion and 1 rain ischemia at 85 rain of perfusion or to (B) 3x I min ischemia at 40 rain, 60 rain, and 85 min of perfusion. ~ntracellular concentrations of ATP, phosphocreatine (PCr) and intracellular inorganic phosphate (P) were assessed using 3~p nuclear magnetic resonance spectroscopy (NMR). Purine catabolite concentration in the coronary effluent was determined by HPLC. Mechanical function of the heart (left ventricular developed pressure -LVDP) was determined using a balloon inserted into the left ventricle. Both in (A) and (B) P. increased two fold during 1 min ischemia at 40 min of perfumon. PCr decreased concomitantly by 30% but no change n ATP was seen. Prior 1 min ischemia at 85 rain of perfusion, ATP concentration was 65%, Pi was 60% and PCr 180% of the initial values in group (A) whilst these concentrations remained unchanged relative to starting levels in group (B). During 1 rain ischemia at 85 rain, concentrations of P. and PCr reached the same levels as during the first ischemic incident both in group (A) and (B). Relative change in comparison to values ,~nmediately before was thus much more pronounced in group (A). Purina catabotite release increased by 0.5/JM immediately after 1 rain ischemia at 40 min, but only by 0.05 pM at 85 min in group (A). These increases in purine release remained unchanged in group (B) during 1 rain ischemia at 40, 60 and 85 rain. Contractile function (LVDP) recovered to value before 10 rain ischemia in group (A) and was maintained constant in group (B). In summary, despite ten fold reduction in purine catabolite release, myocardial concentrations of P. and PCr during 1 rain ischemia before and after 10 rain ischemia wer~ similar and lower was only ATP concentration during the second 1 rain ischemic event. However, PCr level was higher and P. concentration lower prior to second 1 rain ischemic incident. Conse~luently, decreased nucleotide catabolite production in our experimental model seems to be related to reduction of nucleotide pool size and/or increased phosphorylation status before ischemia, but involvement of other factors still can not be excluded.
M.R.S. Group, Cardiothoracic Surgery, National Heart and Lung Institute at Harefield Hospital, Harefield, Middx UB9 6JH, U.K.
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A.P.A+ Steqmann. M.W. Honders, R. Willemze. J.E. Landeqent.
Acquired drug resistance to the dC-analogues AraC and AzadC in the treatment of AML, one of the major obstacles for longterm beneficial therapy, is often associated with deficiency of the pyrimidine nucleoside kinase dCk. Recently, in human T-cell lines this lack of enzymatic activity was shown to be associated with mutations in the dCk-gene, leading to severely reduced levels of the enzyme. We used cell lines derived from an in vivo rat model for AML to study mutational loss of dCk activity and the mechanisms underlying these mutations. One cell line (RCL/0) is sensitive to the drugs and has a normal dCk activity, a second (RCL/A) displays AraCand AzadC-resistance that was induced ex vivo in the animal model; it shows no dCk-activity for AraC and AzadC, as well as a severely impaired enzyme activity for the metabolization of dC. We exposed RCL/O cells to gradually increasing concentrations of either AraC or AzadC and thus generated two independant AraC-and AzadC-resistant cell lines (RCL/0-A and RCL/D resp.). Using RT-PCR-techniques with oligonucleotide primers chosen from the human dCk coding region , all AraC-resistant cell lines were shown to express dCk-specific sequences with aberant restriction sites as compared to amplicons generated from the (normal) dCk-mRNA coding region of RCL/0. Southern blot analysis of RCL/A and RCL/0-A genomic DNA revealed a genomic rearrangement of the dCk gene.
In the AzadC-resistant RCL/D no aberrant PCR-amplicons or Southern hybridization patterns were detected. SSCP analysis however suggests a point mutation in the RCL/D dCk-gene. The data suggest distinct mutational events, underlying AraC-and AzadC-resistance respectively, in this model.
DETERMINATION OF PHOSPHORIBOSYLPYROPHOSPHATE
SYNTHETASE ACTIVITY. A NEW SIMPLIFIED METHOD. R.J. Torres. F.A. Mateos. J.G. Pui~, Phosphorlbosytpyrophosphate synthetase (PRPPs) superactivity is an inherited inborn error of metabolism which causes gout with over-excretion of uric acid associated, in some instances, with neurodevelopmental impairment. Screening for defects in PRPPs activity is complicated by the variety of kinetic alterations detected among affected families, being the most common the catalytic and the regulatory defeCts. Currently employed methods for measurement of PRPPs activity are cumbersome and expensive, requiring an auxiliary enzyme reaction, a radioactive nucleobase, and multiple incubations. The aim of the present study is to describe a simplified, single step, nonisotopic method for determination of PRPPs in hemolysate.
Charcoal-treated hemolysate is incubated in a pH 7.4 reaction mixture containing: 50 mM TfisC1H, 5 mM MgC12, 1 mM EDTA, 0.4 mM DTT, 0.5 mM ATP, 0.35 mM Ribose 5-phosphate, 32 mM NaH2PO4 and 0.25 mM PI-P5 flladenosin 5' pentaphosphate (Ap5A, an inhibitor of the adanylate kinase). The reaction is stopped by addition of 0.1 M EDTA, and the samples are centrifuged in Amicon cones. The resulting filtrate is injected into an HPLC ,aBondapak C18 column and eluted with 0.2 M KH2PO4, pH 6, at 1.3 ml/min. Absorbance is measured at 254 nm, and PRPPs activity is expressed as nmol of AMP generated/h/ mg hemoglobin.
Adenylate kinase activity is fully inhibited by Ap5A, allowing the accurate determination of AMP. The method is sensitive and reproducible, being PRPPs activity linear with the amount of added hemolysate and with time of incubation, and mean and variance values (91.9 _+ 17.8 nmollh/mg) compare closely with those reported using other, more complicated, assay procedures (1). There is a significant correlation between the PRPPs activity measured by this one step assay and the PRPPs activity determined by a modification of the two step assay employing adenine phosphoribosyltransferase as coupled enzyme (r=0.993, p<0.001). The hyperbolic curve relating Pi concentration to initial reaction velocity is shifted to sigmoidal by addition of 0.02 mM GDP whioh inhibite PRPPs activities only at Pi concentrations < 2 raM. This suggezt that this method should provide sensitive and accurate screening for regulatory as well as catalytic defects underlying PRPPs superactivity.
We conclude that the new method presented has important adventages over the currently employed methods, and may provide a valuable diagnostic tool for a better understanding of the metabolic basis of uric acid overproduction and gout. 6-Mercaptopurine (6MP) is used in the maintenance treatment of children with acute lymphoblastic leukemia. Extensive intranellular metabolism of 6MP is required for its oytotoxicity. First, 6MP is converted into thin-IMP (tIMP) by the enzyme hypoxanthine guanine phosphoribosyltransferase, tIMP is a branch-point in 6MP metabolism. The first route of tIMP metabolism is conversion into thioguanine nocleotides by enzymes of the purine interconversion pathway. In this route IMP dehydrogenase (IMPDH) is the rate-limiting enzyme. Thioguanine nuclenddes are incorporate~l into DNA of the cells, inducing delayed cytotoxicity. In general it is accepted that this is the main caus~ for 6MP cytotoxicity. The second route for tIMP metabolism is methylation into methyl-thio-IMP (ModMP). This reaction is catalyzed by the S-adenosylmethionine (SAM) dependent enzyme thiopurine methyltransfera.se in a conversion by which S-adenosyl-Lhomocysteine is formed. Me-tIMP is a strong inhibitor of the purine de novo synthesis. Inhibition of this pathway leads to a depletion of porine nucleotides, and induces inhibition of DNA synthesis. This metabolic route may also contribute to cellular cytotoxieity. In this study the importance of the methylation route for 6MP cytotoxicity was studied in Molt F4 human malignant lymphoblasts. Cells were treated with 6MP combined with mycophenolic acid, an inhibitor of IMPDH, and therefore an inhibitor of formation of thioguanine nucleotides. As a result of addition of 0.5 #M MPA to treatment with 2 .uM 6MP, less thio-GMP and more Me-tIMP were formed. Under these conditions cytotoxicity was increased as compared to 6MP alone. As a result of addition of AICAR, an intermediate of the purine de novo synthesis to the treatment with 6MP and MPA, cytotoxicity resembled that of MPA alone. We therefore concluded that methylation is important for 6MP cytotoxicity. Furthermore, we determined the effects of 6MP on the SAM and the SAH concentradons in Molt F4 cells. Treatment with 6MP decreased SAM, and increased SAH COncentration as compared to untreated ceils. SAM is an important methyl-donor in eukariotic cells, and is involved in methylation of DNA, RNA, proteins and phospholipids. So, any effect on the SAM/SAH ratio may exert effects on these methylation reactions. Therefore, imbalance of the SAM/SAH ratio may he an other important mechanism by which 6MP induces deregulation of cellular processes, which may ultimately result in cellular cytotoxicity. Cytosolic 5'-anclentidase, an ubiquitous enzyme which preferentially hydrolyzes 6-hydroxypufine nucleoside monophosphate% is regulated by energy charge, 2,3-diphosphogiycerate and phosphate (1) (2) (3) . The enzyme appears to be present at higher concentration in cells and organs with high nucleic acid turnover (4). Cytosolic 5'-nuclcotidase behaves as a bifunctional enzyme since it catalyzes the transfer of phosphate from a nucleoslde monophosphate to a nucleoside aceeptor, probably forming an enzyme-phosphate intermediate, thus operating a mononucleotide int~annversion (5) . In the absence of a suitable nuchioside, the enzyme-phosphate complex is hydroiytically cleaved. The understanding of the regulation of the two activities of this enzyme is depending on the possibility to measure the rate of formation of the three reaction products: phosphate, nuclenside, and mononucleotide, in the same assay condition. Cytosolic 5' nucleotidase, has been purified to electrophoretic homogeneity from calf thymus. Its characteristics resulted to be identical to those of the enzyme purified from human colon carcinoma (2) .We developed analytical methods utilizing HPLC and Capillary Electrophoresis to follow both enzyme activities as a fimction of pH and energy charge variation, as well as nudeoside acceptor and nucleotide donor concentrations. Our preliminary results indicate that the two activities show different optimum pH. Furthermore both activities are increased in the presence of high energy charge, hut they display different ratios. In fact, 5'-nucleotidase is the main activity at low energy charge and slightly acidic pit, while phosphotransferase is favoured at high energy charge and pH around the neutrality. The study of the regulation of the enzyme is of great importance for the understanding both of its physiological role, and of its role in the "activation" or "inactivation" of purine prodmgs. Therefore, we studied this relationship in HL-60 human promyelocytic cell-line cells.
EIq'HANCED EXPRESSION OF THE CTP-SYNTHETASE GENE AFTER DEPLETION OF ITS END PRODUCT CTP
HL-60 cells were incubated with 25 MM of 3'-deazauridine (DAU), with i00 ~M of cytidine (Cyd) or 1.25 % DMSO. Initially, this led to a progressive depletion of the CTP pool (DAU), an increased CTP pool (Cyd) or an unchanged CTP pool (DMSO). RNA was purified from all HL-60 cells. The expression of the CTP-synthetase gene at the level of its mRNA was determined after hybridisation with radiolabeled DNA probes of the CTP-synthetsae gene. During incubation with DAU, the amount of CTP-synthetase mRNA was increased in CTP depleted cells after 2 to 24 hours. Beyond 24 hours, the mRNA encoding the CTP-synthetase was decreased and finally became undetectable.
Also, in the presence of DMSO, the mRNA for CTP-synthatse diappeared within 48 hours. Because the HL-60 cells differentiated into functional neutrophilic cells, both after treatment with DAU and treatment with DMSO, it might be that the down-regulation of the CTP-synthatse gene is directly related to the maturation process.
In cells incubated with Cyd, the changes that Occurred in the amounts of CTP-synthetase mRNA are being studied now. A human cerebellum kgtl0 cDNA library was used to isolate additional AMPD2 clones using, as a probe the previously described 5' human Tcell lymphoblast clone: Hut6A (2). Sixteen positive plaques were isolated and the recombinant inserts from twelve were subcloned and sequenced. Nucleotide sequence alignments between these and existing human AMPD2 cDNA clones has demonstrated three divergent extreme 5'-ends, which contribute at least 500 bp to the known sequence. Accordingly, a human AMPD2 genomic clone was used to identify three exons which contain the new 5'-end sequences. Subsequent RNase protection analyses were used to demonstrate both cassette and mutually exclusive alternative splicing events involving the three identified exons. At the predicted protein level, our results indicate at least two different extreme N-terminii. These data, therefore, infer an additional level of complexity to isoform L expression in human tissues and cells. Thymine-uraciluria can be the result of a deficiency of one of the enzymes: dihydropyrimidine dehydrogenase (DHPD, EC 1.3.1.2) or dihydropyrimidinase (DHP, EC 3.5.2.2). DHPD activity can be measured in lymphocytes, monocytes, fibroblasts and liver. In contrast, DHP activlty is not expressed in leukocytes or fibroblasts and therefore has to be measured in liver. As DHPD deficiency is a recently discovered disorder, it is important to investigate whether the defect is equally expressed in the tissues mentioned. We had the opportunity to study leukocytes and fibroblasts in the family of a patient with the defect.
ALTERNATIVE SPLICING EVENTS IN THE 5'-END OF THE HUMAN
Patient BRB, a boy aged 2 yr, was investigated for metabolic abnormalities because of psychomotor retardation and ocular abnormalities.
He appeared to have thymine-uraciluria.
It was decided to investigate also his parents and 2 brothers, although healthy, for this abnormality.
For this purpose 24 h urine samples, blood and skin biopsies were collected from the patient and his family. In the patient thymine-uraciluria was confirmed, while the pyrimidine excretion profiles of the family members were normal.
The activity of DHPD was measured in lymnhocytes and cultured fibroblasts after incubation with 2-~C thymine by HPLC analysis and on-line radioactivity measurement of the reaction products. DHPD activities were undetectably low in the lymphocytes and fibroblasts from the patient. In one brother they were normal, while the other brother and the parents showed intermediate values. The results from the measurements in both tissues led to identical conclusions, giving support to the assumption that leukocytes as well as fibroblasts are appropriate for confirmation of the diagnosis on the enzyme level.
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